Investigational New Drugs

, Volume 19, Issue 2, pp 125–141

Role of Formulation Vehicles in Taxane Pharmacology

  • Lia van Zuylen
  • Jaap Verweij
  • Alex Sparreboom
Article

Abstract

The non-ionic surfactants Cremophor EL (CrEL) and Tween 80,both used as formulation vehicles of many (anticancer) agentsincluding paclitaxel and docetaxel, are not physiologicalinert compounds. We describe their biological properties,especially the toxic side effects, and their pharmacologicalproperties, such as modulation of P-glycoprotein activity. Indetail, we discuss their influence on the disposition of thesolubilized drugs, with focus on CrEL and paclitaxel, and ofconcomitantly administered drugs. The ability of thesurfactants to form micelles in aqueous solution as well asbiological fluids (e.g. plasma) appears to be of greatimportance with respect to the pharmacokinetic behavior of theformulated drugs. Due to drug entrapment in the micelles,plasma concentrations and clearance of free drug changesignificant leading to alteration in pharmacodynamiccharacteristics. We conclude with some perspectives related tofurther investigation and development of alternative methodsof administration.

Cremophor EL paclitaxel Tween 80 docetaxel pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI: The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325–2327, 1971PubMedGoogle Scholar
  2. 2.
    Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15: 141–147, 1993PubMedGoogle Scholar
  3. 3.
    Dorr RT: Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28: S11–S14, 1994PubMedGoogle Scholar
  4. 4.
    Hoffmann H: Polyoxyäthylenglycerol triricinoleat 35 DAC 1979. Pharm Zeit 129: 1730–1733, 1984Google Scholar
  5. 5.
    Goldspiel BR: Guidelines for administration. In: McGuire WP, Rowinsky EK (eds) Paclitaxel in Cancer Treatment. Marcel Dekker Inc, New York, 1995, pp 175–186Google Scholar
  6. 6.
    Onetto N, Dougan M, Hellmann S, Gustafson N, Burroughs J, Florczyk A, Canetta R, Rozenweig M: Safety profile. In: McGuire WP, Rowinsky EK (eds) Paclitaxel in Cancer Treatment. Marcel Dekker, New York, 1995, pp 21–149Google Scholar
  7. 7.
    Hayes FA, Abromowitch, Green AA: Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep 69: 439–441, 1985PubMedGoogle Scholar
  8. 8.
    Howrie DL, Ptachcinski RJ, Griffith P, Hardesty RJ, Rosenthal JT, Burckart GJ, Venkataramanan R: Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm 19: 425–427, 1985PubMedGoogle Scholar
  9. 9.
    Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla R, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263–1268, 1990PubMedGoogle Scholar
  10. 10.
    Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997Google Scholar
  11. 11.
    Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, Burroughs J, Rozencweig M: Overview of Taxol safety. J Natl Cancer Inst Monogr 15: 131–139, 1993PubMedGoogle Scholar
  12. 12.
    Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, Van Der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabárbara P, Onetto N, Winograd B, Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654–2666, 1994PubMedGoogle Scholar
  13. 13.
    Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED: Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97: 42–46, 1996PubMedGoogle Scholar
  14. 14.
    Watkins J, Ward AM, Appleyard TN: Adverse reactions to intravenous anaesthetic induction agents. Br Med J 2: 1084–1085, 1977PubMedGoogle Scholar
  15. 15.
    Hüttel MS, Schou Olesen A, Stoffersen E: Complementmediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth 52: 77–79, 1980PubMedGoogle Scholar
  16. 16.
    Szebeni J, Muggia FM, Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90: 300–306, 1998PubMedGoogle Scholar
  17. 17.
    Van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A: Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 11: 315–324, 2000PubMedGoogle Scholar
  18. 18.
    Lorenz WM, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A: Histamine release in dogs by Cremophor EL and its derivatives: oxyethelated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977PubMedGoogle Scholar
  19. 19.
    Bergh M, Magnusson K, Nilsson JL, Karlberg AT: Contact allergenic activity of Tween 80 before and after air exposure. Contact Dermatitis 37: 9–18, 1997PubMedGoogle Scholar
  20. 20.
    Lesser GJ, Grossman SA, Eller S, Rowinsky6EK: The distribution of systemically administered [3H]-paclitaxel in rats: a quantitiative autoradiographic study. Cancer Chemother Pharmacol 37: 173–178, 1995PubMedGoogle Scholar
  21. 21.
    De Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF: Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 317: 861–886, 1987PubMedGoogle Scholar
  22. 22.
    Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O: Limited oral bioavailability and active epithelia excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 4: 2031–2035, 1997Google Scholar
  23. 23.
    Meerum-Terwogt JM, Malingré MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M, Schellens JHM: Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5: 3379–3384, 1999PubMedGoogle Scholar
  24. 24.
    Evans WC: Drugs containing acids, alcohols and esters. In: Pharmacognosy, 13th ed. Baillière Tindall, London, 1989, p 333Google Scholar
  25. 25.
    Windebank AJ, Blexrud MD, Groen PC: Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268: 1051–1056, 1994PubMedGoogle Scholar
  26. 26.
    Brat DJ, Windebank AJ, Brimijoin S: Emusifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 261:803–810, 1992PubMedGoogle Scholar
  27. 27.
    Podratz JL, Windebank AJ: Dialyzer associated neurotoxicity due to a change in fatty acid structure. Trans Am Soc Neurochem 24: 229, 1993Google Scholar
  28. 28.
    Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495–505, 1994PubMedGoogle Scholar
  29. 29.
    Roman ID, Monte MJ, Esteller A, Jimenez R: Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, CrEL. Transplant 48: 554–558, 1989Google Scholar
  30. 30.
    Chan FK, Shaffer EA: Cholestatic effects of cyclosporin in the rat. Transplant 63: 1574–1578, 1997Google Scholar
  31. 31.
    Luke DR, Kasiske BL, Matzke GR, Awni WM, Keane WF: Effects of cyclosporine on the isolated perfused rat kidney. Transplant 43: 795–801, 1987Google Scholar
  32. 32.
    Besarab A, Jarrell BE, Hirsch S, Carabasi RA, Cressman MD, Green P: Use of the isolated perfused kidney model to assess the acute pharmacologic effets of cyclosporine and its vehicle, cremophor EL. Transplant 44: 195–201, 1957Google Scholar
  33. 33.
    Abraham JS, Bentley FR, Garrison RN, Cryer HM: The in-fluence of the cyclosporine vehicle, Cremophor EL, on renal microvascular blood flow in the rat. Transplant 52: 101–105, 1991Google Scholar
  34. 34.
    Rothenberg ML: Taxol, Taxotere and other new taxanes. Curr Opin Invest Drugs 2: 1269–1277, 1993Google Scholar
  35. 35.
    Drori S, Eytan GD, Assaraf YG: Potentiation of anticancerdrug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228: 1020–1029, 1995PubMedGoogle Scholar
  36. 36.
    Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D: Measurement of CrEL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85: 1685–1690, 1993PubMedGoogle Scholar
  37. 37.
    Sparreboom A, Van Tellingen O, Huizing MT, Nooijen WJ, Beijnen JH: Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B 681: 355–362, 1996Google Scholar
  38. 38.
    Sparreboom A, Loos WJ, Verweij J, De Vos AI, Van der Burg MEL, Stoter G, Nooter K: Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255: 171–175, 1998PubMedGoogle Scholar
  39. 39.
    Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A: Linearized colorimetric assay for Cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. Anal Biochem 261: 198–202, 1998PubMedGoogle Scholar
  40. 40.
    Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A: Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5: 2918–2924, 1999PubMedGoogle Scholar
  41. 41.
    Kunkel M, Meyer T, Bohler J, Keller E, Frahm AW: Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids. J Pharm Biomed Anal 21: 911–922, 1999PubMedGoogle Scholar
  42. 42.
    Oszi Z, Petho G: Quantitative determination of polysorbate 20 in nasal pharmaceutical preparations by high-performance liquid chromatography. J Pharm Biomed Anal 18: 715–720, 1998PubMedGoogle Scholar
  43. 43.
    Smullin CF, Wetterau FP, Olanski VL: The determination of polysorbate 60 in foods.J Am Oil Chem Soc 48: 18–20, 1971PubMedGoogle Scholar
  44. 44.
    Smullin CF: Quantitative determination of polysorbate 60 in non-standard salad dressings. J Assoc Off Anal Chem 61: 506–507, 1978PubMedGoogle Scholar
  45. 45.
    McKean DL, Pesce AJ: Determination of polysorbate in ascites fluid from a premature patient. J Anal Toxicol 9: 174–176, 1985PubMedGoogle Scholar
  46. 46.
    Kato H, Nagai Y, Yamamoto K, Sakabe Y: Determination of polysorbates in foods by colorimetry with confirmation by infrared spectrophotometry, thin-layer chromatography, and gas-chromatography. J Assoc Off Anal Chem 72: 27–29, 1989PubMedGoogle Scholar
  47. 47.
    McKean DL, Pesce AJ, Koo W: Analysis of polysorbate and its polyoxyethylated metabolite. Anal Blochem 161: 348–351, 1987Google Scholar
  48. 48.
    Meerum Terwogt JM, Van Tellingen O, Nannan Panday VR, Huizing MT, Schellens JHM, Ten Bokkel Huinink WW, Boschma MUS, Giaccone G, Veenhof CHN, Beijnen JH: Cremophor EL pharmacokinetics in a Phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. Anticancer Drugs 11: 687–694, 2000PubMedGoogle Scholar
  49. 49.
    Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88: 1297–1301, 1996PubMedGoogle Scholar
  50. 50.
    Sparreboom A, Verweij J, van der Burg MEL, Loos WJ, Brouwer E, Viganó L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937–1942, 1998PubMedGoogle Scholar
  51. 51.
    Nannan Panday VR, Huizing MT, Van Tellingen O, Hakvoort RA, Willemse PHB, De Graeff A, Vermorken JB, Beijnen JH: Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving taxol. In: Clinical Pharmacology of Paclitaxel and Platinum Compounds. Academic Thesis, Utrecht University, 1999, pp 109–120Google Scholar
  52. 52.
    Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A: Disposition of [G-3H]paclitaxel and Cremophor EL in a patient severely impaired renal function. Drug Metab Dispos 27: 1300–1305, 1999PubMedGoogle Scholar
  53. 53.
    Nelson MF, Poulas TA, Gongwer LE, Kischman JC: Preparation of carbon-14-labeled polyoxyethylene (20) sorbitan monolaurate and their metabolitic fate in rats. J Food Sci 31: 253–258, 1966Google Scholar
  54. 54.
    Culver PJ, Wilcox CS, Jones CM, Ross RS: Intermediary metabolism of certain polyoxyethylene derivatives in man. I. Recovery of the polyoxyethylene moiety from urine and feces following ingestion of polyoxyethylene (20) sorbitan monooletate and of polyoxyethylene (40) monostearate.J Pharmacol Exp Ther 103: 377–381, 1951PubMedGoogle Scholar
  55. 55.
    Elworthy PH, Treon JF: Physiological activity of nonionic surfactants. In: Schick M (ed) Nonionic Surfactants, Surfactant Science Series, Vol 1. Marcel Dekker, New York, 1967, pp 923–970Google Scholar
  56. 56.
    Azmin MN, Stuart JFB, Florence AT: The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 14: 238–242, 1985PubMedGoogle Scholar
  57. 57.
    Treon JF, Gongwer LE, Nelson MF, Kischman JC: Physiology and metabolic patterns of non-ionic surfactants In: Paquot P (ed) Chemistry, Physics and Application of Surface-active Substances, vol 3. Gordon and Breach, London, 1967, p 381Google Scholar
  58. 58.
    Azmin MN, Stuart JFB, Calman KC, Florence AT: Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice. Cancer Chemother Pharmacol 9: 161–164, 1982PubMedGoogle Scholar
  59. 59.
    Sparreboom A, Van Tellingen O, Nooijen W, Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112–2115, 1996PubMedGoogle Scholar
  60. 60.
    Sparreboom A, Van Zuyien L, Brouwer E, Loos6WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454–1457, 1999PubMedGoogle Scholar
  61. 61.
    Kessel D, Woodburn K, Decker D, Sykes E: Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Oncol Res 7: 207–212, 1995PubMedGoogle Scholar
  62. 62.
    Sykes E, Woodburn K, Decker D, Kessel D: Effect of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 70: 401–404, 1994PubMedGoogle Scholar
  63. 63.
    Knemeyer I, Wientjes MG, Au JL-S: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44: 241–248, 1999PubMedGoogle Scholar
  64. 64.
    Van Tellingen O, Huizing MT, Nannan Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335, 1999PubMedGoogle Scholar
  65. 65.
    Kearns CM: Pharmacokinetics of the taxanes. Pharmacotherapy 17: 105S–109S, 1997PubMedGoogle Scholar
  66. 66.
    Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmcokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13: 180–190, 1995PubMedGoogle Scholar
  67. 67.
    Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N: Clinical pharmacokineties and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599–606, 1995PubMedGoogle Scholar
  68. 68.
    Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of Taxol given as a 24-hour infusion every 21 days, responses observed in metastatic melanoma. J Clin Oncol 5: 1232–1239, 1987PubMedGoogle Scholar
  69. 69.
    Sparreboom A, Verweij J, Van Zuylen L, Karlsson MO: A pharmacokinetic model for micellar encapsulation of paclitaxel in Cremophor EL. (Abstract). Proc Am Assoc Cancer Res 41: 522, 2000Google Scholar
  70. 70.
    Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH: Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7: 78–86, 1996PubMedGoogle Scholar
  71. 71.
    Ellis AG, Webster LK: Inhibiton of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 43: 13–18, 1999PubMedGoogle Scholar
  72. 72.
    Kessel D: Properties of Cremophor EL micelles probed by fluorescence. Photochem Photobiol 56: 447–451, 1992PubMedGoogle Scholar
  73. 73.
    Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906–1915, 1997PubMedGoogle Scholar
  74. 74.
    Webster LK, Cosson EJ, Stokes KH, Millward MJ: Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73: 522–524, 1996PubMedGoogle Scholar
  75. 75.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JIF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM: Phase I trial of Cremophor EL with bolus doxorubicin. Clin Cancer Res 4: 2321–2329, 1998PubMedGoogle Scholar
  76. 76.
    Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M: Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 10: 391–395, 1999PubMedGoogle Scholar
  77. 77.
    Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713–2721, 1996PubMedGoogle Scholar
  78. 78.
    Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV: A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colonystimulating factor for relapsed epithelial ovarian cancer. Clin Cancer Res 5: 1299–1305, 1999PubMedGoogle Scholar
  79. 79.
    Ellis AG, Crinis NA, Webster LK: Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol38: 81–87, 1996PubMedGoogle Scholar
  80. 80.
    Woodburn K, Chang CK, Lee S, Henderson B, Kessel D: Biodistribution and PIDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem Photobiol 60: 154–159, 1994PubMedGoogle Scholar
  81. 81.
    Kurlansky PA, Sadeghi AM, Michler RE, Coppey LJ, Re LP, Thomas WG, Smith CR, Reemtsma K, Rose EA: Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. J Heart Transplant 5: 312–316, 1986PubMedGoogle Scholar
  82. 82.
    Kay NH, Uppington J, Sear JW, Douglas EJ, Cockshott ID: Pharmacokinetics of propofol (Diprivan) as an induction agent. Postgrad Med J 61: 55–57, 1985PubMedGoogle Scholar
  83. 83.
    Harrison SD, Cusic AM, McAfee SM: Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume. Eur J Cancer 17: 387–389, 1981PubMedGoogle Scholar
  84. 84.
    Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M: Influence of polysorbate 80 (Tween 80) and etoposide (VP–16–213) on the pharmacokinetics and urinary excretion of Adriamycin and its metabolies in cancer patients. Cancer Chemother Pharmacol 17: 80–84, 1986PubMedGoogle Scholar
  85. 85.
    Bourgeois H, Gruia G, Dieras V, Kalla S, Giaccetti S, Cvitkovic E, Aussel JP, Azli N, Riva A, Poullart P, Misser JL: Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: a Phase I dose finding study. (Abstract) Proc Am Assoc Clin Oncol 15: 148, 1996Google Scholar
  86. 86.
    Sandstrom M, Simonsen LE, Freijs A, Karlsson MO: The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemother Pharmacol 44: 469–474, 1999PubMedGoogle Scholar
  87. 87.
    Eposito M, Venturini M, Vannozzi MO, Tolino G, Lunardi G, Garrone O, Angiolini C, Viale M, Bergaglio M, Del Mastro L, Rosso R: Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetic of epirubicin in breast cancer patients. J Clin Oncol 17: 1132–1138, 1999PubMedGoogle Scholar
  88. 88.
    D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A: Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Sem Oncol 25: 16–20, 1998Google Scholar
  89. 89.
    Gannt L, Crochman N, Dyniewicz JM: Effect of a detergent on gastro-intestinal absorption of a steroid. Lancet 1: 486, 1961PubMedGoogle Scholar
  90. 90.
    Hikal AH: Effect of polysorbate 80 on the apparent partition coefficient of drugs on their intestinal absorption in the rat: II. Phenobarbital. Int J Pharm 7: 205–210, 1981Google Scholar
  91. 91.
    Katzemi K, Arita T, Muranishi S: Absorption and excretion of drugs: XXVI. Effect of non-ionic surface-active agents on rectal absorption of sulphonamides. Chem Pharm Bull 13: 976–980, 1965PubMedGoogle Scholar
  92. 92.
    Masters JR, McDermott BJ, Jenkins WE, Fenwick E, Shah PJ, Mundy AR, Loadman PM, Bibby MC: Thiotepa pharmacokinetics during intravesical chemotherapy and the in-fluence of Tween 80. Cancer Chemother Pharmacol 25: 267–273, 1990PubMedGoogle Scholar
  93. 93.
    Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I: Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199–4203, 1990PubMedGoogle Scholar
  94. 94.
    Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH: Reversal of multidrug resistance by surfactants. Br J Cancer 66: 62–68, 1992PubMedGoogle Scholar
  95. 95.
    Friche E, Jensen PB, Sehested M, Demant EF, Nissen NN: The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 2: 297–303, 1990PubMedGoogle Scholar
  96. 96.
    Schuurhuis GJ, Broxterman HJ, Pinedo HM, Van Heijningen THM, Van Kalker CK, Vermorken JB, Spoelstra EC, Lankelma J: The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 62: 591–594, 1990PubMedGoogle Scholar
  97. 97.
    Chervinsky DS, Brecher ML, Hoelcle MJ: Cremophor-EL enhances Taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res 13: 93–96, 1993PubMedGoogle Scholar
  98. 98.
    Hwang M, Ahn C-H, Pine PS, Yin JJ, Hrycyna CA, Licht T, Aszalos A: Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int J Cancer 65: 389–397, 1996PubMedGoogle Scholar
  99. 99.
    Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA:Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 267: 24995–25002, 1992PubMedGoogle Scholar
  100. 100.
    Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS: Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 319: 309–315, 1995PubMedGoogle Scholar
  101. 101.
    Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Millward MJ: Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 39: 557–560, 1997PubMedGoogle Scholar
  102. 102.
    Sparreboom A, Van Asperen J, Van Tellingen O, Smit JW, Schinkel AH, Nooijen WJ, Beijnen JH: Pharmacokinetics of paclitaxel in mdr1a P-glycoprotein deficient mice after intravenous and oral administration (Abstract).Ann Oncol 7: 91, 1996PubMedGoogle Scholar
  103. 103.
    Slater L, Sweet P, Wetzel M, Stupecky M, Osann K: Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 19: 543–548, 1995PubMedGoogle Scholar
  104. 104.
    Watanabe T, Nakayama Y, Naito M, Oh-hara T, Itoh Y, Tsuruo T: Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs 7: 825–832, 1996PubMedGoogle Scholar
  105. 105.
    Nooter K, Sonneveld P: Clinical relevance of P-glycoprotein expression in hematological malignancies. Leuk Res 18: 233–243, 1994PubMedGoogle Scholar
  106. 106.
    Ross DD, Wooten PJ, Tong Y, Cornblatt B, Levy C, Sridhara R, Lee EJ, Schiffer CA: Synergistic reversal of multidrug resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL. Blood 83: 1337–1347, 1995Google Scholar
  107. 107.
    Solomon MB, Meenem B, Heavey C, Paietta E: Differential modulation of P-glycoprotein, the multidrug resistance mediator, by Cremophor in normal versus leukemic hematopoietic cells. Blood 86: 4385–4386, 1995PubMedGoogle Scholar
  108. 108.
    Tsujino I, Yamazaki T, Matsutani M, Sawada U, Horie T: Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells. Cancer Chemother Pharmacol 43: 29–34, 1999PubMedGoogle Scholar
  109. 109.
    Hacker M, Koeferl M, Hong CB: Cremophor and Emulphor induced alterations of serum lipids and lipoprotein electrophoretic patterns of dogs. Res Commun Chem Pathol Pharmacol 31: 119–128, 1981PubMedGoogle Scholar
  110. 110.
    Bertoncello I, Kriegler AB, Woodcock DM, Williams B, Barber L, Nilsson SK: Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil. Int J Radiat Biol 67: 57–64, 1995PubMedGoogle Scholar
  111. 111.
    Ennis M, Lorenz W, Gerland W, Heise J: Isolation of mast cells from rabbit lung and liver: comparison of histamine release induced by the hypnotics Althesin and propanidid. Agents Actions 20: 219–222, 1987PubMedGoogle Scholar
  112. 112.
    Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M: Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 21: 246–250, 1988PubMedGoogle Scholar
  113. 113.
    Shimomura T, Fujiwara H, Ikawa S, Kigawa J, Terakawa N: Effects of Taxol on blood cells. Lancet 352: 541–542, 1998Google Scholar
  114. 114.
    Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Sem Oncol 22: 16–23, 1995Google Scholar
  115. 115.
    Huizing MT, Keung AC, Rosing H, Van der Kuij V, Ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JR: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinumpretreated ovarian cancer patients. J Clin Oncol 11: 2127–2135, 1993PubMedGoogle Scholar
  116. 116.
    Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R: A general model for time-dissociated pharmacokineticpharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63: 11–25, 1998PubMedGoogle Scholar
  117. 117.
    Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, lgarashi T, Itoh K: Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64: 511–521, 1998PubMedGoogle Scholar
  118. 118.
    Nygren P, Csóka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin O, Tholander B, Kreuger A, Lönnerholm G, Jakobsson Å, Olsen L, Kristensen J, Larsson R: The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer 71: 478–481, 1995PubMedGoogle Scholar
  119. 119.
    Csóka K, Dhar S, Fridborg H, Larsson R, Nygren P: Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Cancer 15: 1225–1233, 1997Google Scholar
  120. 120.
    Fjällskog ML, Frii L, Bergh J: Paclitaxel induced cytotoxicity – the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer 30A: 687–690, 1994PubMedGoogle Scholar
  121. 121.
    Fjällskog ML, Frii L, Bergh J: Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet 342: 873, 1993Google Scholar
  122. 122.
    Crispens CG, Sorenson JRJ: Treatment of reticulum cell carcinoma in SJL/J mice with Tween 80. Anticancer Res 8: 1341–1344, 1988PubMedGoogle Scholar
  123. 123.
    Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H, Gundersen G: Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75: 1744–1752, 1997PubMedGoogle Scholar
  124. 124.
    Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: Cytotoxic studies of paelitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104–1109, 1993PubMedGoogle Scholar
  125. 125.
    Liebmann J, Cook JA, Mitchell JB: Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 342: 1428, 1993Google Scholar
  126. 126.
    Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331–339, 1994PubMedGoogle Scholar
  127. 127.
    Rose WC: Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3: 311–321, 1992PubMedGoogle Scholar
  128. 128.
    Fujimoto S: Study for modifying activity of solvents on antitumor activity of paclitaxel. Gan To Kagaku Ryoho 21: 665–670, 1994(Japanese)PubMedGoogle Scholar
  129. 129.
    Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG: Analysis of exposure times and dose escalation of paclitaxel In ovarian cancer cell lines. Cancer 74: 1891–1898, 1994PubMedGoogle Scholar
  130. 130.
    Reinecke P, Corvin J, Gabbert HE, Gerharz CD: Antiproliferative effects of paclitaxel (Taxol) on human renal clear cell carcinomas in vitro. Eur J Cancer 33: 1122–1129, 1997PubMedGoogle Scholar
  131. 131.
    Engblom P, Pulkkinen JO, Rantanen V, Hirvonen H, Kulmala J, Grènman R, Grènman S: Effects of paclitaxel with or without Cremophor EL on cellular clonogenic survival and apoptosis. Eur J Cancer 35: 284–288, 1999PubMedGoogle Scholar
  132. 132.
    Gianni L, Munzone E, Capri A, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995PubMedGoogle Scholar
  133. 133.
    Gehl J, Boesgaard M, Paalke T: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7: 687–693, 1996PubMedGoogle Scholar
  134. 134.
    Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU: Prospective assessment of cardiac toxicity during a randomized Phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24: S17–65–S17–68, 1997Google Scholar
  135. 135.
    Sledge GW: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 22: 123–125,1995PubMedGoogle Scholar
  136. 136.
    Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC: Sequences of taxol and cisplatin: a Phase I and pharmacologic study. J Clin Oncol 9: 1692–1703, 1991PubMedGoogle Scholar
  137. 137.
    Pronk LC, Schellens JHM, Planting AST, Van den Bent MJ, Hilkens PH, Van der Burg MEL, De Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 1071–1079, 1997PubMedGoogle Scholar
  138. 138.
    Schellens JHM, Ma J, Bruno R, Paccaly D, Vergniol JC, Planting AST, De Boer-Dennert M, Van der Burg MEL, Stoter G, Verweij J: Pharmacokinetics of cisplatin and Taxotere (docetaxel) and PBL DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/ Taxotere in a Phase I/II study in solid tumor patients (Abstract). Proc Am Soc Clin Oncol 13: 132, 1994Google Scholar
  139. 139.
    Ma J, Verweij J, Planting AST, De Boer-Dennert M, Van Ingen HE, Van der Burg MEL, Stoter G, Schellens JHM: Current sample handling methods for measurement of cisplatin-DNA-adducts in leukocytes in man lead to discrepant results in DNA-adduct levels and DNA-repair. Br J Cancer 71: 512–517, 1995PubMedGoogle Scholar
  140. 140.
    De Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, DeBruijn P, Ruijgrok EJ, Van der Burg MEL, Stoter G, Sparreboom A: Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol 8: 1145–1150, 1997PubMedGoogle Scholar
  141. 141.
    Zhao F-K, Chuang LF, Israel M, Chuang RY: Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem Biophys Commun 159: 1359–1367, 1989Google Scholar
  142. 142.
    Van der Burg MEL, De Wit R, Logmans A, Van Lent M, Stoter G, Verweij J: Phase I study of weekly cisplatin and weekly or four weekly taxol in patients with advanced ovarian cancer. Eur J Cancer 33: S245, 1997Google Scholar
  143. 143.
    Huizing MT, Giaccone G, van Warmerdam WC, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: A European Cancer Centre (ECC) trial. J Clin Oncol 15: 317–329, 1997PubMedGoogle Scholar
  144. 144.
    Van Warmerdam LCJ, Huizing MT, Giaccone G, Postmus PE, Ten Bokkel Huinink WW, Van Zandwijk N, Koolen MG, Helmerhorst TJ, Van der Vijgh WJ, Veenhof CH, Beijnen JH: Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 24(Suppl 2): 97–104, 1997Google Scholar
  145. 145.
    Millward MJ, Webster LK, Rischin D, Ellis AG, Linahan BM, Maisano R, Toner GC, Stokes KH: Randomised, crossover trial to determine the effect of cremophor on the pharmacokinetics and pharmacodynamics or carboplatin-based therapy (Abstract). Ann Oncol 9(Suppl 2): 130, 1998Google Scholar
  146. 146.
    Kennedy MJ, Zahurak ML, Donehower R, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783–791, 1996PubMedGoogle Scholar
  147. 147.
    Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Grochow LB, Sartorius S, Chen TL, Bowling K, Duerr M, Rowinsky EK: Sequence-dependent hematological toxicity associated with 3-hour paclitaxel/cyclophosphamide doublet. Clin Cancer Res 4: 349–356, 1998PubMedGoogle Scholar
  148. 148.
    Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zulewski J, O'shaughnessy JA: Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14: 95–102, 1996PubMedGoogle Scholar
  149. 149.
    Ibrahim NK, Ellerhorst JA, Theriault RL, Rivera E, Esmaeli B, Legha SS, Ring SE, Soon-Shiong P, Benjamin RS, Hortobagyi GN: Phase I study of Cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel (Abi-007) in solid tumors (Abstract). Proc Am Assoc Clin Oncol 18: 609F, 2000Google Scholar
  150. 150.
    Fumoleau P, Tubiana-Hulin M, Soulié P, Delecroix V, Sistac F, Mefti F, Soulas F, Appia F, Lebecq A, Vergniol JC, Vernillet L, Riva A: A dose finding and pharmacokinetic (PK) Phase I study of a new formulation of docetaxel (D) in advanced solid tumors (Abstract). Ann Oncol 9(Suppl 2): 101, 1998PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Lia van Zuylen
    • 1
  • Jaap Verweij
    • 1
  • Alex Sparreboom
    • 1
  1. 1.Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek)University Hospital RotterdamRotterdamThe Netherlands

Personalised recommendations